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OBJECTIVES This study was undertaken to assess the hematologic, clinical, and biochemical response to
intravenous iron in patients with chronic heart failure (CHF) and anemia.
BACKGROUND Anemia is common in patients with CHF and is associated with higher morbidity and
mortality. The combination of erythropoietin (EPO) and iron increases hemoglobin (Hb) and
improves symptoms and exercise capacity in anemic CHF patients. It is not known whether
intravenous iron alone is an effective treatment for anemia associated with CHF.
METHODS Sixteen anemic patients (Hb 12 g/dl) with stable CHF (age 68.3  11.5 years, 12 men, 9
participants New York Heart Association [NYHA] functional class II and the remainder class
III, left ventricular ejection fraction 26  13%) received a maximum of 1 g of iron sucrose by
bolus intravenous injections over a 12-day treatment phase in an outpatient setting. Mean
follow-up was 92  6 days.
RESULTS Hemoglobin rose from 11.2  0.7 to 12.6  1.2 g/dl (p  0.0007), Minnesota Living with
Heart Failure (MLHF) score fell (denoting improvement) from 33  19 to 19  14 (p 
0.02), 6-min walk distance increased from 242  78 m to 286  72 m (p  0.01), and all
patients recorded NYHA class II at study end (p  0.02). Changes in MLHF score and
6-min walk distance related closely to changes in Hb (r  0.76, p  0.002; r  0.56, p 
0.03, respectively). Of all baseline measurements, only iron and transferrin saturation
correlated with increases in Hb (r  0.60, p  0.02; r  0.60, p  0.01, respectively). There
were no adverse events relating to drug administration or during follow-up.
CONCLUSIONS Intravenous iron sucrose, when used without concomitant EPO, is a simple and safe therapy
that increases Hb, reduces symptoms, and improves exercise capacity in anemic patients with
CHF. Further assessment of its efficacy should be made in a multicenter, randomized,
placebo-controlled trial. (J Am Coll Cardiol 2006;48:1225–7) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.015College of Cardiology Foundation
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tnemia co-exists in up to 55% of patients with chronic heart
ailure (CHF) (1), and retrospective analyses of therapeutic
rials in CHF patients have found anemia at trial entry to be
n independent risk factor for hospitalization and death (2).
he combination of erythropoietin (EPO) and intravenous
r oral iron has been shown to improve cardiac function,
ymptoms, and peak oxygen consumption in patients with
HF and anemia (3,4). Although intravenous iron alone
ncreases and maintains hemoglobin (Hb) in patients with
enal disease (5), there are no reported studies into the effects
f intravenous iron alone in patients with CHF and anemia.
ETHODS
atient population. We conducted a prospective, uncon-
rolled, open-label study of the intravenous administration
f iron sucrose (Venofer; Vifor, Switzerland) in patients
ith systolic heart failure and Hb 12 g/dl who had been
table on standard heart failure medication for 6 weeks.
From the *Department of Clinical Cardiology, The Heart Hospital, London,
nited Kingdom; and †Clinical Heart Failure Service, West Middlesex University
ospital, Isleworth, United Kingdom. This study was funded by an unconditional
esearch grant from Syner-Med (PP) Ltd., the U.K. distributor of Venofer (iron
ucrose).
Manuscript received April 10, 2006; revised manuscript received July 7, 2006,
ccepted July 10, 2006.itamin B12 or folic acid deficiency, hemoglobinopathy, or
erum ferritin 400 ng/ml were exclusion criteria. The local
esearch and ethics committee gave study approval. Written,
nformed consent was obtained from all participants.
tudy protocol. In an outpatient setting, patients received
00 mg (10 ml) bolus injections of undiluted iron sucrose
ver 10 min into a peripheral vein on days 1, 3, and 5 of the
tudy. Serum ferritin was measured on day 12 and, if 400
g/ml, further 200 mg doses were administered on days 15
nd 17. Follow-up time was 3 months.
valuations. Symptoms were assessed according New
ork Heart Association (NYHA) functional classification
nd the Minnesota Living with Heart failure (MLHF)
uestionnaire. Exercise capacity was quantified using a 6-min
alk (6MW) test. Blood samples were taken for determi-
ation of hematologic variables, iron indexes, and renal
unction. All patients were considered for gastrointestinal (GI)
ndoscopy as investigation into the cause of their anemia.
tatistical analyses. All results are reported as mean
alues  SD. Paired and unpaired Student t tests, analysis
f variance with Fisher post hoc test, simple linear regres-
ion analysis (all Statview 5, SAS Institute Inc., Cary, North
arolina) and McNemar’s test (IFA Services, Amsterdam,
he Netherlands) were used as appropriate. The p values
0.05 are referred to as having statistical significance.
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eventeen patients were enrolled, and 16 completed the
tudy. The mean age was 68.3  11.5 years, and 12
articipants were men. Heart failure was due to coronary
rtery disease in 13, dilated cardiomyopathy in 2, and valve
isease in a single patient. At study entry, 9 participants had
YHA class II symptoms, the remainder class III. Mean
eft ventricular ejection fraction was 26  13%. All patients
ere taking loop diuretics, 15 were taking angiotensin-
onverting enzyme inhibitors or angiotensin receptor block-
rs, 5 were taking beta-blockers, and 8 were taking aldac-
one. Mean follow-up was 92  6 days. Fourteen patients
eceived 5 doses (1,000 mg) of iron sucrose, and 2 patients
eceived 3 doses (mean dose 950  137 mg).
ffect of iron sucrose on hematologic parameters. He-
oglobin rose from 11.2  0.7 to 12.6  1.2 g/dl (p 
.0007) (Fig. 1), serum iron from 9.2  4.4 to 13.7  4.8
mol/l (p 0.009), ferritin from 87 113 ng/ml to 217
85 (p  0.004), and transferrin saturation from 16.0  9.5
o 24.6  8.4% (p  0.009). Of all baseline measurements,
nly iron and transferrin saturation correlated with increases
n Hb (r 0.60, p 0.02; r 0.60, p 0.01, respectively).
urthermore, when divided into tertiles according to change
n Hb, patients demonstrating the greatest response were
hose with the lowest baseline iron levels (p  0.006 vs. the
ertile with the lowest response). Although there was no
hange in serum creatinine or calculated creatinine clearance
Cockcroft-Gault formula), there was a trend toward a fall
n cystatin C concentration (1.71 0.52 to 1.50 0.53 mg/l,
 0.08), suggesting improved glomerular filtration rate.
ffect of iron sucrose on symptoms and exercise capacity.
t follow-up, all patients were in NYHA functional class II
p 0.02 vs. baseline), and MLHF score also fell (denoting
mprovement) from 33  19 to 19  14 (p  0.02). Mean
MW distance increased from 242  78 m to 286  72 m
p 0.01). Changes in MLHF score and in 6MW distance
orrelated strongly with increases in Hb (r  0.76, p 
.002 and r  0.56, p  0.03, respectively) (Fig. 2). Left
entricular ejection fraction did not significantly change
27  12% at study end).
I pathology and response to iron sucrose. Of the 14
atients that underwent GI endoscopy, 6 had gastroesoph-
gitis, 1 peptic ulcer disease, and 1 a benign colonic polyp.
he remainder had no identifiable disease. Those with GI
Abbreviations and Acronyms
CHF  chronic heart failure
EPO  erythropoietin
Hb  hemoglobin
GI  gastrointestinal
MLHF  Minnesota Living with Heart Failure
NYHA  New York Heart Association
6MW  6-min walkathology did not have lower serum iron, ferritin, or
w
iransferrin saturation at baseline nor did they demonstrate a
reater increase in Hb compared with those without GI
athology (p  NS for all comparisons).
afety and tolerability. Iron sucrose was well tolerated with
o instance of local or systemic adverse reactions. During
ollow-up, no patients were hospitalized, and none died. There
ere no changes to loop diuretic dose, and there was no
tatistical difference between baseline and completion body
eights.
ISCUSSION
his study demonstrates that intravenous administration of
ron sucrose to patients with CHF and anemia results in a
ignificant increase in Hb, a reduction in symptoms, and an
mprovement in exercise capacity. These effects were achieved
ithout simultaneous EPO therapy.
Iron deficiency is present when transferrin saturation is
16% and ferritin 30 ng/ml (6). Seven patients (44%) in
his study were iron deficient by these criteria, and they had
he greatest response to iron sucrose (increase in Hb 2.1 
.3 g/dl vs. 0.9  1.0 g/dl in the iron replete group, p 
.06). Iron status is also the leading determinant of EPO
esponsiveness in patients with chronic renal failure, and
oncomitant intravenous iron is an essential adjunct in this
ontext. We found no association between GI pathology
nd iron deficiency or response to iron, suggesting dietary
actors or malabsorption may also influence iron status in
atients with CHF.
igure 1. Changes in hemoglobin (Hb) for each participant after treatment
ith iron sucrose. Baseline and completion Hb  SD for the whole group
s denoted by the values between the error bars.
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September 19, 2006:1225–7 Iron Therapy for Anemia in Heart FailureGiven that the risk of death in CHF increases with small
eductions in Hb (2), modest increases in Hb should confer
ignificant clinical benefits. This is supported by the obser-
ations that peak oxygen consumption in CHF correlates
ith Hb levels (7), and the correction of anemia improves
his measure of exercise capacity (4). The mean increase in
b in this study was 1.4  1.3 g/dl (range: 0.7 to 3.1
/dl) for a treatment phase of just 5 to 17 days encompass-
ng only 4 or 6 hospital visits. Others have recorded mean
ncreases of 2.6 g/dl (3) and 3.3 g/dl (4) using a combination
f EPO and iron in similar CHF groups. Although the
PO/iron combination may result in a greater response
han iron alone, there are clearly individuals who have a
ramatic hematologic and clinical response to the latter.
The fact that we recorded no adverse events relating to
he administration of iron sucrose or during follow-up is
onsistent with other safety data concerning the use of this
rug. After a total of 2,297 injections of iron sucrose in 657
atients with renal failure, Macdougall and Roche (8)
eported adverse events in only 2.5%. All were short-lived,
nd no patient required hospitalization. Furthermore, iron
ucrose appears safe in patients with known intolerance of
ther parenteral iron preparations (9).
Intravenous iron sucrose, without concomitant EPO, is
simple and safe therapy that increases Hb, reduces
ymptoms, and improves exercise capacity in anemic
atients with CHF. Further assessment of its efficacy
hould be made in multicenter, randomized, placebo-
igure 2. Relationships between change in hemoglobin and changes in Minnontrolled trials.eprint requests and correspondence: Dr. Aidan P. Bolger,
epartment of Adult Cardiology, The Heart Hospital, 16-18
estmoreland Street, London W1G 8PH, United Kingdom.
-mail: aidan@bolgers.org.
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